Poly Medicure Limited has announced its unaudited financial results for the third quarter and nine months ended December 31, 2025. The company reported a consolidated revenue of ₹493.7 crore for Q3 FY26, a significant increase of 16.4% compared to ₹424.2 crore in Q3 FY25. For the nine-month period (9M FY26), consolidated revenue grew by 9.1% to ₹1340.7 crore from ₹1229.0 crore in 9M FY25. The consolidated Operating EBITDA for Q3 FY26 stood at ₹119.4 crore, a marginal increase of 2.8% from ₹116.1 crore in the previous year, with an EBITDA margin of 24.2%. For the nine months, consolidated Operating EBITDA grew by 2.7% to ₹345.3 crore. Profit After Tax (PAT) for Q3 FY26 was ₹70.8 crore, a decrease of 16.9% compared to ₹85.2 crore in Q3 FY25. However, for the nine-month period, PAT saw a growth of 3.6% to ₹255.7 crore from ₹246.8 crore in 9M FY25. Key business updates include a 16.2% domestic revenue growth and 14.1% international revenue growth QoQ. The company has adequate liquidity with ₹839.8 crore in cash and cash equivalents as of December 31, 2025, and has invested ₹234 crore in capex during 9MFY26. Poly Medicure also launched 19 new products in 9M FY26 and has a strong R&D team. The company received regulatory approval from DCGI for its Intravenous Lithotripsy System (IVL) and Drug Eluting Balloon (DEB).
